- Vince Holding Corp VNCE shares dipped 25 percent to $0.975. Vince reported a delay in fiscal 2016 10-K filing.
- Skyline Corporation SKY shares tumbled 23.8 percent to $6.44. Skyline posted a Q3 net loss of $2,447,000, or $0.29 per share, versus year-ago net loss of $520,000 or $0.06 per share.
- Oncomed Pharmaceuticals Inc OMED shares dropped 18.7 percent to $3.88 as the company disclosed that its Phase 2 trial of tarextumab did not meet endpoints. OncoMed also reported that it will discontinue enrollment in Phase 1B clinical trial of brontictuzumab.
- Snyder's-Lance Inc LNCE shares fell 18.5 percent to $32.55. Snyder's-Lance announced the retirement of its CEO and issued a weak forecast.
- Immune Pharmaceuticals Inc IMNP shares dropped 11.8 percent to $2.25 after declining 2.67 percent on Thursday.
- Apricus Biosciences Inc APRI shares dropped 11.3 percent to $1.72. Apricus Biosciences filed for offering of up to $6 million of units.
- China Auto Logistics Inc CALI shares fell 11.1 percent to $2.66.
- Incyte Corporation INCY dropped 11 percent to $125.34. The FDA on Friday declined to approve Eli Lilly and Co and Incyte arthritis drug Olumiant. PiperJaffray downgraded Incyte from Overweight to Neutral.
- Timkensteel Corp TMST declined 10.9 percent to $15.77. TimkenSteel projects Q1 net sales of around $309 million on 280,000 ship tons and a net loss of around $5 million.
- Biostar Pharmaceuticals Inc BSPM shares dropped 10.8 percent to $2.03. Biostar Pharmaceuticals reported a FY16 net loss of $5.7 million on sales of $2.4 million.
- Adeptus Health Inc ADPT shares declined 9.8 percent to $2.11.
- Akari Therapeutics PLC (ADR) AKTX fell 9.6 percent to $14.48. Chardan Capital reiterated Akari Therapeutics with a Sell and raised the price target from $5.00 to $6.50.
- GWG Holdings Inc GWGH shares declined 9 percent to $9.60 after dropping 5.62 percent on Thursday.
- SemiLEDs Corporation LEDS shares dropped 8.6 percent to $2.87.
- Eli Lilly and Co LLY fell 4.1 percent to $82.39. The FDA on Friday declined to approve Eli Lilly and Incyte arthritis drug Olumiant. BMO Capital downgraded Eli Lilly from Market Perform to Underperform.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: NewsMovers & ShakersIntraday UpdateMarketsAnalyst RatingsConsumer StaplesMid-Day LosersPackaged Foods & MeatsTop Losers
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
